| 1. |
|
|
| 2. |
- Högberg, Thomas, et al.
(författare)
-
Gynekologisk onkologi
- 2008. - 2
-
Ingår i: Onkologi. - Stockholm : Liber. - 9789147084012 ; , s. 488-533
-
Bokkapitel (övrigt vetenskapligt/konstnärligt)
|
|
| 3. |
- Wennergren, Göran, 1947
(författare)
-
Medicinarminnen som fängslar
- 2019
-
Ingår i: Läkartidningen. - 0023-7205. ; 116
-
Recension (övrigt vetenskapligt/konstnärligt)
|
|
| 4. |
- Loman, Niklas
(författare)
-
Clinical Aspects of Hereditary Breast Cancer
- 2003
-
Doktorsavhandling (övrigt vetenskapligt/konstnärligt)abstract
- A positive family history of breast cancer (BC) is one of the strongest predictors of the disease. Two major BC susceptibility genes, BRCA1 and BRCA2 were identified about a decade ago. In this thesis, studies of different biological. clinical and epidemiological aspects of hereditary BC are presented. In the first paper data on the expression of steroid hormone receptors in hereditary BC are presented. We confirm previously published data regarding the paucity of estrogen and progesterone receptors in BRCA1-associated BC, and report new findings in BRCA2-associated tumours and cases with an unidentified hereditary factor. Hormone receptor levels in these two groups do not differ significantly from each other or from an age-matched control population unselected for family history. The second paper is a cohort study of cancer incidence in relatives of BRCA1 and BRCA2 germline mutation carriers. Other cancers than BC and ovarian cancer do not appear to be greatly increased and require specific follow-up in carriers. The third study is a retrospective case-control study on the prognosis and clinical presentation of BRCA2-associated BC. BC in families with an identified BRCA2 mutation seemed to present at a more advanced stage at diagnosis compared with age and year of diagnoses matched controls. This translated into an increased risk to die from BC in this group, but overall survival was not significantly decreased. The fourth study is a population-based study of family history and BRCA1 and BRCA2 mutations in BC cases below the age of 41. A positive family history was very frequent in this group of young BC patients. About one-third of them had a family history including at least one first- or second-degree relative with BC. A positive BRCA1-mutation status was observed in 6.8% of the cases, and BRCA2-mutations were seen in 2.1% of the in women. BRCA1 and BRCA2 mutations were more prevalent in younger women, in women with a positive family history including at least one first-degree relative with breast or ovarian cancer, and in women that had already or did develop a bilateral BC during a median follow-up of 5.5 years. In the fifth study relative and cumulative cancer incidence in the first-degree relatives of the woman of the previous study were calculated and compared with the population. The BC risk was still increased in first-degree relatives of women with early-onset BC (below the age of 41) when BRCA-mutation carriers were excluded, in addition an association with prostate cancer was suggested. The risk of prostate cancer did only appear to be increased in relatives of women with BC below the age of 36. Furthermore, cumulative BC incidences were calculated for women with different hereditary backgrounds.
|
|
| 5. |
|
|
| 6. |
- Anderzén-Carlsson, Agneta, 1966-
(författare)
-
Att hantera rädsla hos barn med cancer
- 2008
-
Ingår i: Onkologi i Sverige. - 1653-1582. ; 4:6, s. 14-20
-
Tidskriftsartikel (populärvet., debatt m.m.)
|
|
| 7. |
|
|
| 8. |
- Johansson, Jonas, 1970-
(författare)
-
Comparative Treatment Planning in Radiotherapy and Clinical Impact of Proton Relative Biological Effectiveness
- 2006
-
Doktorsavhandling (övrigt vetenskapligt/konstnärligt)abstract
- The development of new irradiation techniques is presently a very active field of research with increased availability of more sophisticated modalities such as intensity modulated photons (IMRT), protons and light ions. The primary aim of this work is to evaluate if the dose-distributions using IMRT and protons contribute to clinical advantages. A secondary aim is to investigate the potential clinical implication of the increased relative biological effect (RBE) for protons at the end of the Bragg peak. The potential benefits are evaluated using physical dose measures and dose-response models for normal tissue complication probability (NTCP) and tumour control probability (TCP). Comparative treatment planning was performed using three locally advanced tumour types, left-sided node positive breast cancer, hypopharyngeal cancer, and rectal cancer. All studies showed that both IMRT and protons could improve the dose distributions compared to 3D-CRT, and significantly improve treatment results with lower NTCPs and, concerning hypopharyngeal cancer, higher TCP. Protons always resulted in smaller volumes receiving intermediate and low radiation doses.Using protons or IMRT for left-sided node-positive breast cancer, the advantage is a significantly decreased risk for cardiac mortality (from 6.7% to 1%) and radiation induced pneumonitis (from 28.2% to less than 3%) compared to 3D-CRT. For hypopharyngeal cancer, protons and IMRT provide more selective treatment plans, higher TCP since a simultaneous boost technique is feasible, and better parotid gland sparing for several patients. For locally advanced rectal cancer, the NTCP for small bowel is potentially reduced by approximately 50% using IMRT or protons; protons have an even greater potential if the structure of the small bowel is parallel.A variable RBE correction is developed and applied to a clinical proton treatment plan. A significant difference is obtained compared to the commonly accepted RBE correction of 1.1. This indicates that a variable RBE may be of importance in future proton treatment planning.This thesis provides support for increased use both IMRT and proton radiotherapy, although stronger for protons. Therefore, investments in proton facilities with capacity for large clinical trials can be supported.
|
|
| 9. |
- Nilsson, Daniel, 1973, et al.
(författare)
-
[New possibilitys in surgery for brain tumors with intraoperative MRI]. : Intraoperativ MRT ger nya möjligheter för neurokirurgi.
- 2019
-
Ingår i: Läkartidningen. - 1652-7518. ; 116
-
Tidskriftsartikel (refereegranskat)abstract
- In surgery for brain tumors, the main challenge is to resect the tumor completely without causing injury to surrounding structures. Intraoperative MRI can provide updated information on remaining tumor and the relationship to critical brain structures. We report our initial experiences from an intraoperative 3 T MRI suite from a surgical, radiological and anesthesiological perspective. The technique has been useful in treating pediatric brain tumor patients, pituitary tumors, low-grade gliomas and epilepsy surgery patients. Image quality has been comparable to conventional diagnostic MRI and there have been no adverse events from the technique. Team-based training and simulation are key factors to manage this complex technical environment and make intraoperative MRI into a routine procedure.
|
|
| 10. |
|
|
